ProQR Therapeutics N.V.

PRQR Nasdaq SEC CIK 1612940
Follow ProQR Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Revenue, last year €15.9M −15.9% vs prior year
Net income −€42.2M −51.9% vs prior year
EPS, diluted −€0.40 −25% vs prior year
Operating cash flow −€52.8M −45.1% vs prior year
Revenue by fiscal year
€1.4M
€3.6M
€6.5M
€18.9M
€15.9M
FY21 FY22 FY23 FY24 FY25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−€75M−€50M−€25M€0€25MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25€15.9M−€42.2M
FY24€18.9M−€27.8M
FY23€6.5M−€28.1M
FY22€3.6M−€64.4M
FY21€1.4M−€60.7M
FY20-−€46.6M
FY19-−€56.5M
FY18-−€36.9M
FY17-−€43.6M
FY16-−€39.1M
FY15-−€20.8M
FY14--
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−273.1%−265.2%
FY24−161.2%−146.9%
FY23−489.1%−431.7%
FY22−1813%−1792.5%
FY21−4225.3%−4486%
FY20--
FY19--
FY18--
FY17--
FY16--
FY15--
FY14--
Free cash flowOperating cash flow minus capital expenditure
−€75M−€50M−€25M€0€25MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−€53.8M
FY24−€37.8M
FY23€20.2M
FY22−€69.2M
FY21−€26.5M
FY20−€48M
FY19−€44.6M
FY18−€28.8M
FY17−€35.1M
FY16−€36.8M
FY15−€25.5M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • ProQR Therapeutics
  • Healthcare median
−6000%−4000%−2000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearProQR TherapeuticsHealthcare median
FY25−265.2%−30.6%
FY24−146.9%−47%
FY23−431.7%−58%
FY22−1792.5%−80.4%
FY21−4486%−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%